Integrating artificial intelligence ( AI ) into colorectal cancer reporting
The Journal of Pathology · 2026
DOI: 10.1002/path.70029 ↗At a glance
Übersichtsarbeit in The Journal of Pathology, 2026. Written by Konstantin Bräutigam and 4 co-authors. Institution: Centre for Evolution and Cancer, Institute of Cancer Research, London, UK. Major MEDLINE topics: Colorectal Neoplasms, Artificial Intelligence. 202 references. The full text is freely available (open access, CC BY 4.0). Funded by: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Cancer Research UK.
Abstract (original language)
Artificial intelligence (AI) and deep learning (DL) are transforming cancer research and clinical care, with histopathology playing a central role in this transformation. In colorectal cancer (CRC), the second leading cause of cancer mortality world‐wide, multimodal and vision‐language models (VLMs) hold particular promise for enhancing the standardisation of histopathology reporting, the understanding of disease biology, and the discovery of novel prognostic indicators. Despite the availability of guidelines and reporting templates for essential prognostic indicators, variability remains in how key features such as TNM staging or tumour deposits are assessed and reported in routine clinical practice. AI‐based tools have the potential to support refined extraction of established and extended features directly from whole‐slide images. In parallel, recent studies have shown that DL models applied to pathology slides and associated AI‐based biomarkers can outperform traditional histopathological prognostic indicators and uncover novel parameters, including tumour‐adipocyte interactions, tumour‐stroma ratio, and immune cell patterns at the invasive margin. Here, we review recent advances in both domains: AI‐assisted standardisation of CRC pathology reporting and AI‐driven identification of novel prognostic biomarkers. We highlight the need to refine and standardise CRC reporting practices and propose that a harmonised approach combining established pathology features with AI‐derived prognostic indicators could refine risk assessment and improve outcomes for CRC patients. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre for Evolution and Cancer, Institute of Cancer Research, London, UK.
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Computational and Translational Pathology Group, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
- Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
ORCID profiles: Konstantin Bräutigam, Ann-Marie Baker
Funding
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Cancer Research UK
Cite
APA
Bräutigam, K., Baker, A. M., Koelzer, V. H., Kather, J. N., & Graham, T. A. (2026). Integrating artificial intelligence ( AI ) into colorectal cancer reporting. The Journal of Pathology. https://doi.org/10.1002/path.70029
Vancouver
Bräutigam K, Baker AM, Koelzer VH, Kather JN, Graham TA. Integrating artificial intelligence ( AI ) into colorectal cancer reporting. The Journal of Pathology. 2026. doi:10.1002/path.70029
BibTeX
@article{Brutigam2026,
author = {Bräutigam, Konstantin and Baker, Ann-Marie and Koelzer, Viktor H and Kather, Jakob N and Graham, Trevor A},
title = {Integrating artificial intelligence ( AI ) into colorectal cancer reporting},
journal = {The Journal of Pathology},
year = {2026},
doi = {10.1002/path.70029}
}
EUVIMED